Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $82.3 million.

  • Protalix BioTherapeutics' Liabilities and Shareholders Equity rose 3362.57% to $82.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.1 million, marking a year-over-year decrease of 589.65%. This contributed to the annual value of $73.4 million for FY2024, which is 1304.81% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Liabilities and Shareholders Equity is $82.3 million, which was up 3362.57% from $78.5 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Liabilities and Shareholders Equity ranged from a high of $108.2 million in Q2 2021 and a low of $55.8 million during Q4 2022
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $78.5 million (2025), whereas its average is $78.3 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Liabilities and Shareholders Equity tumbled by 4395.77% in 2022, and later soared by 5441.82% in 2023.
  • Protalix BioTherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $73.7 million in 2021, then dropped by 24.27% to $55.8 million in 2022, then surged by 51.35% to $84.4 million in 2023, then dropped by 13.05% to $73.4 million in 2024, then rose by 12.05% to $82.3 million in 2025.
  • Its Liabilities and Shareholders Equity was $82.3 million in Q3 2025, compared to $78.5 million in Q2 2025 and $73.9 million in Q1 2025.